A 26 week double-blind extension to a 26 week randomised, double-blind placebo-controlled study that evaluated the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer's disease.

Axonyx Inc0 个研究点目标入组 450 人开始时间: 2005年3月2日最近更新: 2020年7月27日

适应症

试验速览

暂无简介。

•After successfully completing the AX-CL-09 study, patients will be enrolled in the extension study and will continue to receive study medication without a break (i.e. rollover directly into the extension study).
•In order to be eligible for inclusion in this extension study, patients must have successfully completed the AX-CL-09 study and continue to fulfil the inclusion criteria for the AX-CL-09 study.
•In addition, patients must fulfil the following:
•General health status acceptable for participation in a 6 month extension study;
•Are capable of understanding and have given written informed consent for the extension study [or this has been provided by their acceptable representative (according to local requirements)] and a separate caregiver responsibilities and consent form has also been signed by the patient’s caregiver;
•Have a reliable caregiver available, and if not living in the same household, the caregiver sees the patient at least 4 times a week or a total of 15 to 20 hours per week;
•Agrees to comply with the protocol requirements of the extension study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients who complete the AX-CL-09 study may have received the investigational drug phenserine-tartrate, which is an acetylcholinesterase inhibitor. These patients are eligible for enrolment in the AX-CL-09e extension study providing they have not received any other acetylcholinesterase inhibitor in the 3 months before study entry, and providing they do not fulfil any other exclusion criteria from the AX CL-09 study.

发起方